The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial

Authors
Category Primary study
JournalANNALS OF ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: b9854ba122780288e233c22b618f41df34600905
First added on: Dec 20, 2022